All In Biotech

Drug Trial Radar · NCT02545504

Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 20, 2026Latest source record: May 26, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 432 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

432

Actual

Start

Oct 13, 2015

Primary completion

May 15, 2019

Study completion May 15, 2019

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Sep 10, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to compare the efficacy of andecaliximab (GS-5745) versus placebo in combination with modified fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (OXA) (mFOLFOX6) as measured by overall survival.

Conditions

  • Gastric Adenocarcinoma

Interventions

  • AndecaliximabDrug

    800 mg administered intravenously on Days 1 and 15 of each 28-day treatment cycle

  • PlaceboDrug

    Administered intravenously on Days 1 and 15 of each treatment cycle

  • LeucovorinDrug

    Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle

  • 5-fluorouracilDrug

    Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle

  • OxaliplatinDrug

    Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Andecaliximab + mFOLFOX6 median follow-up at the time of final analysis: 19.43 months; Placebo + mFOLFOX6 median follow-up at the time of the final analysis: 19.45 months

Locations

134 sites in 16 countries. Site status is shown where the registry gives one.

  • Scripps Green Hospital

    La Jolla, California

  • University of Southern California

    Los Angeles, California

  • UCLA Jonsson Comprehensive Cancer Center

    Los Angeles, California

  • Innovative Clinical Research Institute

    Whittier, California

  • Cancer Center of Central Connecticut

    Plainville, Connecticut

  • Omega Research Consultants LLC

    DeBary, Florida

  • Edward Hospital & Health Services

    Naperville, Illinois

  • Parkview Hospital

    Fort Wayne, Indiana

  • Indiana University Goshen Center for Cancer Care

    Goshen, Indiana

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • New England Cancer Specialists

    Scarborough, Maine

  • Karamanos Cancer Institute

    Detroit, Michigan

  • HCA Healthcare

    Kansas City, Missouri

  • Carol G. Simon Cancer Center

    Morristown, New Jersey

  • Regional Cancer Care Associates LLC - Sparta

    Sparta, New Jersey

  • Weill Cornell Medical College - New York Presbyterian Hospital

    New York, New York

  • University of Rochester

    Rochester, New York

  • Duke Cancer Institute

    Durham, North Carolina

  • Oncology Hematology Care, Inc.

    Cincinnati, Ohio

  • The Ohio State Medical Center

    Columbus, Ohio

  • Northwest Cancer Specialists

    Portland, Oregon

  • Charleston Hematology Oncology Associates

    Charleston, South Carolina

  • Prairie Lakes Health Care System INC

    Watertown, South Dakota

  • Tennessee Oncology

    Nashville, Tennessee

  • Center for Cancer Blood Disorders

    Fort Worth, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Texas Oncology-Seton Williamson

    Round Rock, Texas

  • Scott and White Memorial Hospital

    Temple, Texas

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • Virginia Commonwealth University

    Richmond, Virginia

  • Virginia Mason Seattle Main Clinic

    Seattle, Washington

  • The Tweed Hospital

    Tweed Heads, Australia

  • Sydney Adventist Hospital

    Wahroonga, Australia

  • The Canberra Hospital

    Garran, Australian Capital Territory, Australia

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia

  • The Crown Princess Mary Cancer Centre

    Westmead, New South Wales, Australia

  • Princess Alexandra Hospital

    Brisbane, Queensland, Australia

  • Ashford Cancer Centre

    Kurralta Park, South Australia, Australia

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia

  • Epworth Healthcare

    Richmond, Victoria, Australia

Showing 40 of 134 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.